Skip to main navigation
Toggle navigation
linkedin
Twitter
Patients & Caregivers
Our Commitment
Investigational Medicines
Clinical Trials
IDH Mutations in Cancer
Pyruvate Kinase Deficiency
Patient Resources
Our Medicines
Medical Professionals
Careers
Our Values
Inside Agios
Find a Job
Benefits
Commitment to Our Community
Partnering
Investors
Overview
Press Releases
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Analyst Coverage
Financials
SEC Filings
Annual Reports & Proxy
Quarterly Results
Resources
Publications
Investor FAQs
Corporate Governance
Leadership
Board of Directors
Corporate Fact Sheet
Environmental, Social and Governance (ESG) Report
Contact Us
IR Contacts
Information Request
Email Alerts
About Us
Our Values
Leadership
Board of Directors
Scientific Advisors
Founders
Our History
Corporate Responsibility & Sustainability
Research
Our Research Platform
Cancer Metabolism
Rare Genetic Diseases
Metabolic Immuno-Oncology
Publications
Pipeline
Pipeline Overview
Clinical Programs
Preclinical Programs
Our Medicines
News & Events
Press Releases
Events & Webcasts
Contact Us
Investors
Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic diseases.
Stock is
Shareholder Tools
Print Page
RSS Feeds
Email Alerts
IR Contacts
Holly Manning
Director, Investor Relations
Email:
Holly.Manning@agios.com
Resources
FAQs
Email Alerts
Publications